Publicacións en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (2)

2023

  1. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

    eClinicalMedicine, Vol. 62

2018

  1. Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial

    Journal of Infection, Vol. 76, Núm. 3, pp. 258-269